153 related articles for article (PubMed ID: 37658631)
1. P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database.
Morishita H; Perera LMB; Sunakawa H; Kimura S; Yoshida H; Ogihara T
J Clin Pharmacol; 2024 Jan; 64(1):118-124. PubMed ID: 37658631
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
[TBL] [Abstract][Full Text] [Related]
3. QT alterations in psychopharmacology: proven candidates and suspects.
Alvarez PA; Pahissa J
Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
[TBL] [Abstract][Full Text] [Related]
4. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model.
Yao X; Anderson DL; Ross SA; Lang DG; Desai BZ; Cooper DC; Wheelan P; McIntyre MS; Bergquist ML; MacKenzie KI; Becherer JD; Hashim MA
Br J Pharmacol; 2008 Aug; 154(7):1446-56. PubMed ID: 18587422
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein-Mediated Pharmacokinetic Interactions Increase Pimozide hERG Channel Inhibition.
Morishita H; Perera LMB; Zhang X; Mizoi K; Ito MA; Yano K; Ogihara T
J Pharm Sci; 2022 Dec; 111(12):3411-3416. PubMed ID: 36181876
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
Silvestre JS; O'Neill MF; Prous JR
J Psychopharmacol; 2014 Apr; 28(4):329-40. PubMed ID: 24327451
[TBL] [Abstract][Full Text] [Related]
7. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.
Crumb WJ; Ekins S; Sarazan RD; Wikel JH; Wrighton SA; Carlson C; Beasley CM
Pharm Res; 2006 Jun; 23(6):1133-43. PubMed ID: 16715368
[TBL] [Abstract][Full Text] [Related]
8. An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database.
Park SI; An H; Kim A; Jang IJ; Yu KS; Chung JY
Expert Opin Drug Saf; 2016 Aug; 15(8):1013-9. PubMed ID: 27276059
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C; Garcia P; Salvo F; Touafchia A; Galinier M; Sommet A; Montastruc F
Psychopharmacology (Berl); 2023 Jan; 240(1):199-202. PubMed ID: 36515735
[TBL] [Abstract][Full Text] [Related]
10. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
11. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
[TBL] [Abstract][Full Text] [Related]
13. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
14. Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective.
Pollard CE; Valentin JP; Hammond TG
Br J Pharmacol; 2008 Aug; 154(7):1538-43. PubMed ID: 18500356
[TBL] [Abstract][Full Text] [Related]
15. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
Nogawa H; Kawai T; Yajima M; Miura M; Ogawa T; Murakami K
Eur J Pharmacol; 2013 Nov; 720(1-3):29-37. PubMed ID: 24211675
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS.
Chen Y; Fan Q; Liu Y; Shi Y; Luo H
Psychiatry Res; 2023 Aug; 326():115300. PubMed ID: 37364503
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
18. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.
Wallis RM
Br J Pharmacol; 2010 Jan; 159(1):115-21. PubMed ID: 19785646
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.
Wu CS; Tsai YT; Tsai HJ
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25713294
[TBL] [Abstract][Full Text] [Related]
20. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation.
Zemrak WR; Kenna GA
Am J Health Syst Pharm; 2008 Jun; 65(11):1029-38. PubMed ID: 18499875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
